Compare EVGN & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVGN | XBIO |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Israel | United States |
| Employees | N/A | 2 |
| Industry | Agricultural Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 7.5M |
| IPO Year | 2013 | N/A |
| Metric | EVGN | XBIO |
|---|---|---|
| Price | $0.86 | $3.03 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $3.50 | N/A |
| AVG Volume (30 Days) | ★ 131.3K | 24.3K |
| Earning Date | 03-05-2026 | 03-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.81 |
| Revenue Next Year | $73.33 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $1.90 |
| 52 Week High | $2.42 | $13.93 |
| Indicator | EVGN | XBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 60.81 |
| Support Level | $0.81 | $2.64 |
| Resistance Level | $1.23 | $3.12 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 56.57 | 60.47 |
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.